Dry Powder Inhalers (DPIs)
Our dry powder inhalers are derived from the commercially validated AirFluSal™ GyroHaler™ platform, but with a range of user interfaces and payload volumes, giving you confident performance and a proven regulatory track record.
With options for proprietary unit-dose and multidose platforms, as well as off-the-shelf capsule devices, we can support your program from early development to a commercial-ready device.
CAPSULE DPIs
Unit-dose capsule inhaler technology offers flexible dosing and a fast-to-clinic option in early development. Phillips Medisize can support capsule-based DPI programs from pre-clinical development to small-scale commercialization.
BLISTER DPIs
Our commercially validated, blister-based DPI device technology provides confidence of performance for multidose applications.
Choose from a range of options that offer:
- Simple design and low component count
- Intuitive user interfaces
- Broad and long-term patent coverage
- Low cost
DPI PLATFORM PRODUCTS
Open-Inhale-Close (OIC)
- DPI device with only three user steps
- Designed with digital connectivity in mind
Lever-operated Multidose Inhaler (LOMI)
- 60-dose DPI device with four user steps
- Approved and marketed in the US
GyroHaler™
- 60-dose DPI device with intuitive user interface
- Approved and marketed in the UK, EU and Rest of World
F1P Unit-dose Inhaler
- Unit-dose DPI device designed for delivery of higher payload volumes
- Incorporates a cyclone design to assist aerosolization for greater lung deposition
AirFluSal™ is a registered trademark of Novartis AG. GyroHaler™ is a registered trademark of Vectura.
INHALATION THERAPIES EXPERTISE
Built on world-class capabilities, our platform delivers proven inhalation services: product development; formulation expertise; pharmaceutical analysis; bespoke device design; and clinical-trial production and supply.
Featured Resources
